DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence

Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. —> Read More